Bayer Schering Pharma AG, Germany is starting Phase III with an innovative patch for female contraception that combines low dosed ethinylestradiol and gestodene. Approximately 3300 women will be enrolled into two global studies to evaluate the contraceptive reliability of the patch starting in May 2009. It is planned to submit the new patch for registration worldwide. First filing is expected in 2012.
"Bayer Schering Pharma is looking forward to progressing to Phase III trials with our novel patch. It will be the smallest, lowest dosed and the only transparent patch for female contraception on the market," said Phil Smits, M.D., Head of Women's Healthcare at Bayer Schering Pharma. "We are optimistic that these attributes will make it an attractive option for women seeking alternative routes of hormonal contraception."
The patch will be applied once per week, i. e. three patches per cycle (for 21 days) and one week off. The simple handling will make the product convenient to use, and therefore, a good compliance from the user can be anticipated.
About Bayer HealthCare
The Bayer Group is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer HealthCare, a subsidiary of Bayer AG, is one of the worldâs leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Bayer Schering Pharma, Consumer Care and Medical Care divisions. Bayer HealthCareâs aim is to discover and manufacture products that will improve human and animal health worldwide. Find more information at http://www.bayerhealthcare.com.
Bayer Schering Pharma is a worldwide leading specialty pharmaceutical company. Its research and business activities are focused on the following areas: Diagnostic Imaging, General Medicine, Specialty Medicine and Women's Healthcare. With innovative products, Bayer Schering Pharma aims for leading positions in specialized markets worldwide. Using new ideas, Bayer Schering Pharma aims to make a contribution to medical progress and strives to improve the quality of life. Find more information at http://www.bayerscheringpharma.de.
Bayer
Bayer Schering Pharma is starting Phase III studies with an innovative low-dose contraceptive patch
- Details
- Category: Bayer
Business & Industry
- Bayer and Dewpoint Therapeutics sign licensing agreement for heart disease program
- U.S. FDA approves Pfizer's RSV vaccine ABRYSVO® for adults aged 18 to 59 at increased risk for disease
- Roche's Vabysmo improved vision in underrepresented populations with diabetic macular edema (DME) in a first-of-its-kind study
- Bayer submits EU marketing authorization application for elinzanetant to treat moderate to severe vasomotor symptoms
- Novo Nordisk launches new initiative to prevent childhood obesity in disadvantaged urban communities
Research & Development
- Immune cell discovery offers new potential for cancer immunotherapy
- Repurposing mifepristone: new hope for anti-aging treatments
- Expanding access to weight-loss drugs could save thousands of lives a year
- World-first clinical trial for treating spinal cord injury using olfactory cell nerve bridges
- Drug discovery within the patient
- Specific type of DNA could be a target of future cancer therapies
- Gene therapy automatically converts omega-6 to omega-3 fatty acids in the body
Conferences & Events
- New insights into T and B cells offer hope for autoimmune disease sufferers
- SAE Media Group proudly presents the 4th Annual AI in Drug Discovery Conference
- SAE Media Group's 6th annual 3D Cell Culture Conference
- CPHI Frankfurt returns to pre-pandemic strength as pharma industry booms again
- 14th Annual RNA Therapeutics: Investigating the next generation of genetic medicine through RNA based therapies
- CPHI Excellence in Pharma Award Winners 2022
- CPHI Frankfurt Report predicts huge funding overhang to drive contract services growth
Regulatory Affairs
- FDA approves new treatment for hemophilia A or B
- FDA approves nasal spray influenza vaccine for self- or caregiver-administration
- FDA approves first nasal spray for treatment of anaphylaxis
- FDA approves nonsteroidal treatment for Duchenne muscular dystrophy
- FDA approves first gene therapies to treat patients with sickle cell disease